| pubmed-article:17286630 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0013072 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0004454 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0020458 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0006050 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0023660 | lld:lifeskim |
| pubmed-article:17286630 | lifeskim:mentions | umls-concept:C0445115 | lld:lifeskim |
| pubmed-article:17286630 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17286630 | pubmed:dateCreated | 2007-4-26 | lld:pubmed |
| pubmed-article:17286630 | pubmed:abstractText | Botulinum toxin type A represents a safe and effective treatment for primary axillary hyperhidrosis. One of the most troublesome disadvantages associated with this therapy is pain at the injection sites. Reconstitution of botulinum toxin A in a solution of lidocaine could be an easy alternative procedure to reduce the discomfort associated with those injections. However, the current recommendations are that botulinum toxin A should be reconstituted in normal saline. | lld:pubmed |
| pubmed-article:17286630 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17286630 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17286630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286630 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17286630 | pubmed:month | May | lld:pubmed |
| pubmed-article:17286630 | pubmed:issn | 0007-0963 | lld:pubmed |
| pubmed-article:17286630 | pubmed:author | pubmed-author:Vadoud-Seyedi... | lld:pubmed |
| pubmed-article:17286630 | pubmed:author | pubmed-author:SimonartTT | lld:pubmed |
| pubmed-article:17286630 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17286630 | pubmed:volume | 156 | lld:pubmed |
| pubmed-article:17286630 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17286630 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17286630 | pubmed:pagination | 986-9 | lld:pubmed |
| pubmed-article:17286630 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:meshHeading | pubmed-meshheading:17286630... | lld:pubmed |
| pubmed-article:17286630 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17286630 | pubmed:articleTitle | Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. | lld:pubmed |
| pubmed-article:17286630 | pubmed:affiliation | Department of Dermatology, Erasme University Hospital, 808 Route de Lennik, Brussels, Belgium. jvadouds@ulb.ac.be | lld:pubmed |
| pubmed-article:17286630 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17286630 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
